Summary
A phase II single-blind, randomized, placebo-controlled trial to study the efficacy and safety of Study Drug administered as adjunctive treatment to patients with acquired thrombotic thrombocytopenic purpura.
Register to download
PRA Successfully Rescues Phase II Hematology Study
You may also be interested in:
Blog
March is Bleeding Disorders Awareness Month
Read Story
White Paper
The Patient Voice: Engaging Rare Disease Patients Improves Clinical Trial Enrollment & Retention
Clinical trials in rare diseases are complex and present unique challenges. However, patients in these trials are very vocal, with caretakers, family…
View Resource
page
About PRA Health Sciences
We are a global healthcare intelligence partner, consistently ranked among the top CROs and best employers worldwide.
Learn More
View all related content and resources for Rare Diseases
Explore Insights